ARBARR ELECTRONICS LIMITED
Company number NI025382 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
ARBARR ELECTRONICS LIMITED - Analysis Report
Company Number: NI025382
Analysis Date: 2026-05-31 20:41 UTC
Financial Health Assessment of ARBARR ELECTRONICS LIMITED
1. Financial Health Score: D
Explanation:
The company shows serious signs of financial distress as reflected in a negative net asset position and net current liabilities in the most recent year. While historically the business had solid financial footing, the sudden deterioration indicates severe liquidity and solvency concerns. The score D reflects significant financial weakness requiring urgent management intervention.
2. Key Vital Signs
| Metric | 2025 (Latest) | Interpretation |
|---|---|---|
| Net Current Assets (Working Capital) | (£107,868) Negative | Indicates cash flow strain; current liabilities exceed current assets, a red flag—akin to a patient lacking sufficient immediate resources to meet short-term obligations ("short of breath"). |
| Net Assets (Shareholders’ Funds) | (£85,230) Negative | Balance sheet shows insolvency on a going-concern basis; liabilities exceed total assets—"organ failure" symptom warning investors and creditors. |
| Cash in Hand | £415 | Extremely low cash reserves despite current liabilities; cash flow "pulse" nearly flatlining. |
| Current Liabilities | £363,513 | Increased compared to prior year; suggests rising short-term debt and obligations. |
| Share Capital | £21,000 | Stable but relatively small; limited buffer for losses. |
| Intangible Assets (Development Costs) | £236,922 | Significant capitalised development costs; investment in growth potential, though with amortisation charges. |
| Trade Debtors | £652 | Drastically down from previous year; potential problems collecting sales revenue ("patient losing vital fluids"). |
| Stock (Inventory) | £188,044 | Inventory decreased but still a major current asset; risk of tying up funds in unsold goods. |
| Bank Loans and Overdrafts | £259,143 (short & long term) | Substantial borrowed funds; "heavy medication" to support operations. |
3. Diagnosis
Liquidity Crisis: The company’s working capital tanked from a healthy positive £95,502 in 2024 to a negative £107,868 in 2025—an alarming 213% deterioration. This is like a patient whose circulation is blocked and cannot deliver nutrients effectively. The extremely low cash (£415) confirms the company is under severe short-term cash flow stress.
Balance Sheet Erosion: A shift from positive net assets (£37,554 in 2024) to a deficit of (£85,230) in 2025 confirms a structural solvency issue. Liabilities exceeding assets by this magnitude threatens the company’s ongoing viability. It suggests losses absorbed in the year, possibly due to operating losses or asset impairments.
Profitability and Earnings Retention: The Profit and Loss reserve moved deeply negative (£-106,230), signalling accumulated losses. This "chronic illness" shows the company has been "bleeding" cash or value over time.
Asset Composition and Amortisation: High capitalised development costs, with heavy amortisation (£125,352), mean profitability is further squeezed by non-cash charges. While investment in intangibles may bode well for future earnings, the current financial strain overshadows this.
Decrease in Trade Debtors and Cash: A dramatic fall in trade debtors from £8,367 to £652 alongside cash dropping from £36,391 to £415 suggests customers are paying slower or sales are declining, worsening the cash flow "symptoms."
Current Liabilities Growing: Increased bank loans and overdrafts, plus higher creditors and tax liabilities, indicate dependency on external financing and difficulty in settling immediate debts.
Staffing Reduction: Average employee numbers dropped from 15 to 9, possibly a cost-cutting move reflecting operational distress.
Management Changes: One director resigned in late 2023, but the company maintains active director and secretary status, indicating continued governance oversight.
Overall, this financial condition resembles a patient in critical condition with multiple system failures — cash flow, solvency, and profitability all compromised.
4. Recommendations
To stabilize and recover, ARBARR ELECTRONICS LIMITED should consider:
A. Immediate Liquidity Management (Emergency Care):
- Seek short-term financing or renegotiate loan terms to ease immediate cash flow pressure.
- Improve cash collection from debtors by tightening credit control policies.
- Reduce stock levels to free up working capital without harming production.
- Delay non-essential expenditures and capital projects.
B. Structural Financial Rehabilitation (Long-Term Treatment):
- Conduct a detailed profit and loss review to identify loss-making products or operations and cut or restructure these.
- Explore options for equity injection or shareholder support to restore net asset position.
- Evaluate feasibility of selling non-core or underperforming assets to improve liquidity.
- Review amortisation and intangible capitalisation policies to ensure alignment with realistic future economic benefits.
C. Strategic and Operational Review:
- Examine underlying business model in the loaded electronic boards manufacturing sector for competitiveness.
- Assess market conditions, customer base, and supply chain robustness to anticipate future risks or opportunities.
- Strengthen financial planning and forecasting to detect early warning signs ("regular health check-ups").
D. Governance and Compliance:
- Ensure transparent communication with creditors and shareholders about financial status and recovery plan.
- Consider appointing financial advisors or turnaround specialists to guide restructuring.
By proactively diagnosing and addressing these symptoms of distress now, the company improves chances of regaining healthy financial function and avoiding insolvency.